Compare Charles River Laboratories Intl. Inc (CRL) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Marsh & McLennan Companies, Inc. — how do they compare? Charles River Laboratories Intl. Inc trades at $232.4 (market cap $11.14B), while Marsh & McLennan Companies, Inc. trades at $178.2 (market cap $85.78B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 7.7× Charles River Laboratories Intl. Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.22% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | MRSH | |
|---|---|---|
Market Cap | $11.14B | $85.78B |
Sector | Health | Financials |
52-Week High | $233.60 | $212.28 |
52-Week Low | $145.57 | $157.32 |
Enterprise Value | $14.00B | $106.62B |
Dividend Yield | — | 2.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Marsh (MRSH) trades at $181.53, up 1.81% with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $3.29 exceeding expectations. Revenue grew to $26.98B in 2025 with a 14.26% net margin, while recent dividend increases and strategic acquisitions highlight management's confidence in cash flow generation.
The stock presents a balanced outlook with 33% analyst buy ratings and a $203.67 consensus target offering 12% upside. However, elevated valuation ratios and bearish oscillators suggest near-term consolidation risk. Key catalysts include Q2 2026 earnings and sustained organic growth amid easing insurance pricing headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
